



Published in final edited form as:

*Dig Dis Sci.* 2015 April ; 60(4): 819–821. doi:10.1007/s10620-015-3598-8.

## Association of Serotonin Transporter Promoter Polymorphism (5HTTLPR) with Microscopic Colitis and Ulcerative Colitis: Time to Be AsSERTive?

**Dana Goldner and Kara Gross Margolis**

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY, USA

Kara Gross Margolis: Kjg2133@cumc.columbia.edu

Serotonin (5-hydroxytryptamine; 5-HT) is a bioamine neurotransmitter classically recognized for its importance in central nervous system (CNS) functions. Nevertheless, most of the body's serotonin is peripherally located, with over 95 % of the body's 5-HT produced in the intestine, where it modulates motility and secretion [1]. Intestinal 5-HT has also been demonstrated to play a major role in enteric nervous system development, intestinal epithelial homeostasis, and the modulation of intestinal inflammation [2–5]. Despite the recognition that intestinal inflammatory diseases such as ulcerative colitis (UC) can have strong genetic components [6], genetic polymorphisms linked with serotonin have not been associated with these disease states. In this issue of *Digestive Diseases and Sciences*, Sikander et al. [7] conducted the first prospective case–control study to demonstrate that there may be a potential association between polymorphisms in the 5-HT transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR) of the serotonin transporter (SERT) gene promoter and the intestinal inflammatory diseases UC and microscopic colitis (MC).

In the intestine, 5-HT is produced by two different isoforms of the same biosynthetic enzyme, tryptophan hydroxylase (TPH). The vast majority (90 %) of 5-HT is produced by TPH1 in the enterochromaffin (EC) cells (and mast cells in rodents). The remainder is synthesized by TPH2 in enteric neurons [8]. TPH2 is also located in the neurons of the CNS. Under normal conditions, SERT terminates the action of released intestinal 5-HT via uptake into mucosal enterocytes and serotonergic neurons. The remaining 5-HT diffuses into the systemic circulation where it is taken up primarily by platelets which also contain SERT. Because 5-HT does not cross the blood–brain barrier, virtually all 5-HT present in blood is synthesized in the intestine [1, 9, 10]. Further, because platelets do not contain the synthetic machinery necessary to produce 5-HT (TPH), all platelet 5-HT is the result of SERT-mediated uptake. SERT is thus essential for intestinal and blood 5-HT homeostasis. The expression of SERT is regulated in part by a polymorphism in the 5-HTTLPR which has two predominant variant alleles: a short (S) allele and long (L) allele. The S allele is associated with reduced transcriptional efficiency and lower functional expression of SERT relative to

the L allele [11]. It is therefore possible that intestinal and platelet 5-HT levels would be abnormal in individuals harboring an S allele.

Abnormal concentrations of 5-HT could affect an individual's predisposition to or severity of intestinal inflammatory disease. Human studies have revealed a potential role for mucosal 5-HT in intestinal inflammation. Increased enteric 5-HT concentrations are present in patients with Crohn's disease (CD), UC and MC [12–14]. This elevation is associated with significantly increased EC cell numbers and decreased SERT transcription in some studies [15, 16]. Studies have been conflicting, however, in UC where decreased amounts of mucosal 5-HT, TPH1 and SERT immunoreactivity and decreased EC cell numbers have also been observed [16].

Murine models have further supported the contribution of 5-HT toward intestinal inflammation. Mice that lack SERT, and thus have an increase in available intestinal 5-HT, develop more severe colitis when induced by trinitrobenzene sulfonic acid (TNBS) [17]. These mice also develop a more severe spontaneous colitis that arises as a result of interleukin (IL)-10 deletion [18]. Mice that do not produce intestinal mucosal 5-HT because they lack TPH1 are resistant to dinitrobenzene sulfonic acid-induced colitis [19]. Mice or guinea pigs with TNBS-induced colitis also demonstrate SERT downregulation and an increase in EC cell number and/or 5-HT release [9, 20–22].

Extensive research has elucidated part of the complex interrelationship between 5-HT and the immune system. SERT and/or 5-HT receptors are expressed on many cells involved in innate and adaptive immunity, including macrophages, mast cells, dendritic cells, basophils, neutrophils, eosinophils, natural killer cells, B cells and T cells [23]. The modulation of immune cells by 5-HT can have opposing effects; immune cell activation can trigger NF- $\kappa$ B and/or other proinflammatory signaling pathways, thereby stimulating production of proinflammatory mediators [24]. Conversely, activation of the 5-HT<sub>7</sub> receptor, expressed on dendritic cells, helps ameliorate chemically induced colitis [25]. The immune system likewise exerts effects on 5-HT homeostasis. The proinflammatory mediators interferon- $\gamma$  and tumor necrosis factor- $\alpha$  decrease SERT function in colonic adenocarcinoma Caco2 cells [26]. Moreover, IL-1 $\beta$  and lipopolysaccharide-induced 5-HT secretion is significantly increased in EC cells derived from patients with CD compared with a control population [24].

Post-infectious irritable bowel syndrome (IBS) may represent a low-grade inflammatory state and has been associated with increased peak postprandial 5-HT release and EC cell hyperplasia [27, 28]. In investigations of SERT polymorphisms in IBS, a meta-analysis of seven studies concluded that 5-HTTLPR genotypes are unrelated to IBS, while others reported evidence of an association when patients were stratified by predominant clinical symptoms [29]. The most recent meta-analysis of 25 such studies concluded that the L/L genotype of 5-HTTLPR is associated with an increased risk of developing constipation-predominant IBS (IBS-C) [30]. 5-HTTLPR genetic polymorphisms also may provide evidence for the efficacy of serotonin-based therapies for specific subtypes of IBS. In comparison with individuals with S/S or S/L genotypes, diarrhea-predominant IBS patients with the L/L genotype demonstrated a greater response to alosetron, a 5HT<sub>3</sub> antagonist,

while IBS-C patients with the L/L genotype had less of a response to the 5HT4 agonist tegaserod [31, 32].

Sikander et al. [7] conducted a prospective case–control study in which they sought to evaluate the association between the 5-HTTLPR promoter polymorphism and serum 5-HT concentrations in UC and MC. By evaluation of the 5-HTTLPR gene polymorphism in patients categorized as active UC, UC in remission, MC or in healthy controls, the authors found that the frequency of the S/S genotype was significantly lower in patients with MC or UC in remission, relative to healthy controls. They also determined that serum 5-HT levels, as measured by ELISA, were significantly higher in individuals with MC or UC when compared to the control population. More specifically, MC patients with the L/S or S/S genotype had significantly increased serum 5-HT concentrations compared with controls with similar genotypes. Similarly, active UC patients with the S/S genotype had increased serum 5-HT concentrations compared with S/S controls. Mean 5-HT concentrations were highest in individuals expressing the S/S genotype.

This is the first study to suggest that 5-HTTLPR polymorphisms may contribute to the pathogenesis of MC and UC and that these polymorphisms may correlate with serum 5-HT concentrations. Intestinal inflammation could be initiated by the increased amount of available enteric mucosal 5-HT due to a SERT polymorphism. Individuals in this study with the S/S genotype had the highest mean 5-HT levels. It is therefore interesting that individuals with intestinal inflammatory diseases (MC or UC in remission) exhibit the S/S genotype less frequently than controls. This observation is consistent with the hypothesis that 5-HTTLPR might represent only one of the contributing factors to disease severity.

This study describes a novel association between 5-HT, genetic susceptibility variants and intestinal inflammatory disease. Future studies in the field can span into multiple directions. It may be of interest to measure concentrations of free 5-HT in plasma of individuals with intestinal inflammatory diseases. Although only  $\approx 0.1\%$  of 5-HT released can be measured as free 5-HT [33], this pool is accessible to sites of action and receptors that may be important for intestinal serotonergic functions. It would also be interesting to evaluate whether 5-HTTLPR polymorphisms are associated with changes in other important intestinal markers of serotonin homeostasis such as TPH1, 5-HT receptors and mucosal SERT expression as well as EC cell number. Further, the observation that  $>50\%$  of the controls in this study have the S/S genotype demonstrates that the development of MC and UC is not exclusively dependent on the presence of a 5-HTTLPR polymorphism. Future studies may focus on the evaluation of the relationship between 5-HTTLPR polymorphisms and epigenetic factors as well as rare variations in SERT that have been recently discovered [34]. The current study represents an important step toward understanding the complex genetic basis of intestinal inflammatory diseases.

## References

1. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. *Curr Opin Endocrinol Diabetes Obes.* 2013; 20:14–21. [PubMed: 23222853]

2. Li Z, Chalazonitis A, Huang YY, et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. *J Neurosci*. 2011; 31:8998–9009. [PubMed: 21677183]
3. Gross ER, Gershon MD, Margolis KG, et al. Neuronal serotonin regulates growth of the intestinal mucosa in mice. *Gastroenterology*. 2012; 143:408–417. e402. [PubMed: 22609381]
4. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. *Clin Exp Immunol*. 2010; 161:19–27. [PubMed: 20408856]
5. Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. *Gut*. 2014; 63:928–937. [PubMed: 23749550]
6. Van Limbergen J, Radford-Smith G, Satsangi J. Advances in IBD genetics. *Nat Rev Gastroenterol Hepatol*. 2014; 11:372–385. [PubMed: 24614343]
7. Sikander A, Sinha SK, Prasad KK, Rana SV. Association of serotonin transporter promoter polymorphism (5-HTTLPR) with microscopic colitis and ulcerative colitis. *Dig Dis Sci*. (Epub ahead of print).
8. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. *Gastroenterology*. 2007; 132:397–414. [PubMed: 17241888]
9. Margolis KG, Pothoulakis C. Serotonin has a critical role in the pathogenesis of experimental colitis. *Gastroenterology*. 2009; 137:1562–1566. [PubMed: 19789088]
10. Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. *Curr Opin Gastroenterol*. 2009; 25:503–511. [PubMed: 19816171]
11. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. *J Neurochem*. 1996; 66:2621–2624. [PubMed: 8632190]
12. El-Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. *J Intern Med*. 1997; 242:413–419. [PubMed: 9408072]
13. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. *World J Gastroenterol*. 2012; 18:6070–6075. [PubMed: 23155335]
14. Belai A, Boulos PB, Robson T, Burnstock G. Neurochemical coding in the small intestine of patients with Crohn's disease. *Gut*. 1997; 40:767–774. [PubMed: 9245931]
15. Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH, Polak JM. Increased populations of endocrine cells in Crohn's ileitis. *Virchows Archiv A Pathol Anat Histopathol*. 1987; 410:391–396.
16. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. *Gastroenterology*. 2004; 126:1657–1664. [PubMed: 15188158]
17. Bischoff SC, Mailer R, Pabst O, et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. *Am J Physiol Gastrointest Liver Physiol*. 2009; 296:G685–G695. [PubMed: 19095763]
18. Haub S, Ritze Y, Bergheim I, et al. Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter. *Neurogastroenterol Motil*. 2010; 22:826–834. [PubMed: 20219086]
19. Ghia JE, Li N, Wang H, et al. Serotonin has a key role in pathogenesis of experimental colitis. *Gastroenterology*. 2009; 137:1649–1660. [PubMed: 19706294]
20. Linden DR, Foley KF, McQuoid C, et al. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. *Neurogastroenterol Motil*. 2005; 17:565–574. [PubMed: 16078946]
21. Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. *Am J Physiol Gastrointest Liver Physiol*. 2003; 285:G207–G216. [PubMed: 12646422]
22. O'Hara JR, Ho W, Linden DR, Mawe GM, Sharkey KA. Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. *Am J Physiol Gastrointest Liver Physiol*. 2004; 287:G998–G1007. [PubMed: 15231483]

23. Baganz NL, Blakely RD. A dialogue between the immune system and brain, spoken in the language of serotonin. *ACS Chem Neurosci*. 2013; 4:48–63. [PubMed: 23336044]
24. Kidd M, Gustafsson BI, Drozdov I, Modlin IM. IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease. *Neurogastroenterol Motil*. 2009; 21:439–450. [PubMed: 19019013]
25. Kim JJ, Bridle BW, Ghia JE, et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. *J Immunol*. 2013; 190:4795–4804. [PubMed: 23554310]
26. Foley KF, Pantano C, Ciolino A, Mawe GM. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells. *Am J Physiol Gastrointest Liver Physiol*. 2007; 292:G779–G784. [PubMed: 17170025]
27. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? *J Pediatr Gastroenterol Nutr*. 2007; 45:S115–S119. [PubMed: 18185071]
28. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. *J Clin Gastroenterol*. 2005; 39:S184–S193. [PubMed: 15798484]
29. Colucci R, Blandizzi C, Bellini M, et al. The genetics of the serotonin transporter and irritable bowel syndrome. *Trends Mol Med*. 2008; 14:295–304. [PubMed: 18550438]
30. Zhang ZF, Duan ZJ, Wang LX, et al. The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. *BMC Gastroenterol*. 2014; 14:23. [PubMed: 24512255]
31. Li Y, Nie Y, Xie J, et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. *Dig Dis Sci*. 2007; 52:2942–2949. [PubMed: 17394071]
32. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. *Gastroenterology*. 2002; 123:425–432. [PubMed: 12145795]
33. Brand T, Anderson GM. The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. *Clin Chem*. 2011; 57:1376–1386. [PubMed: 21859903]
34. Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD. Enhanced activity of human serotonin transporter variants associated with autism. *Philos Trans R Soc Lond B Biol Sci*. 2009; 364:163–173. [PubMed: 18957375]